Certified Innovation Path in Biotechnology 2027

Closed

Programme Category

EU Competitive Programmes

Programme Name

Funding under projects

Programme Description

Funding provided under previews programmes.

Programme Details

Identifier Code

EIT Health 26-28

Call

Certified Innovation Path in Biotechnology 2027

Summary

EIT Health invites organisations from industry, education and research to submit proposals for the development of a new EIT Label-certified Biotech pathway within the Certified Innovation Path (CIP) portfolio, complementing the existing Health Data, Digital Medical Devices and High Value Care pathways.

Funded projects will design and deliver personalised learning courses for graduates and professionals across the health biotechnology value chain. The pathway will equip participants with the innovation, entrepreneurship and biotech expertise needed to translate scientific advances into scalable, market-ready healthcare solutions across Europe.

EIT Health will co-fund collaborative consortium projects to design and deliver a new Certified Innovation Path (CIP) in Biotechnology, complementing the existing Health Data, Digital Medical Devices and High Value Care pathways.

Detailed Call Description

This EIT Label aligned, personalised learning pathway will target graduates and professionals seeking to upskill across the health biotechnology value chain.

The Biotech Certified Innovation Path must:

  • Equip participants to navigate Europe’s evolving biotech regulatory and policy landscape, including the EU Biotech Act, Clinical Trials Regulation, with a focus on translation from discovery to early clinical development and scale-up.
  • Combine advanced biotech and translational knowledge with EIT-labelled innovation, entrepreneurship and leadership competencies, enabling participants to develop, finance and implement biotech innovation in real-world settings.
  • Foster cross-border collaboration, mobility and industry engagement, connecting European research, clinical, manufacturing and investment ecosystems through applied modules and capstone project

Proposed courses must aim to:

  • Equip participants to navigate and apply Europe’s evolving regulatory and policy landscape, including the EU Biotech Act, Clinical Trials Regulation and MDR/IVDR, with a focus on translation and early scaleup.
  • Integrate advanced biotech and translational expertise with EIT Labelled innovation, entrepreneurship and leadership competencies, enabling real-world implementation of biotech innovation.
  • Strengthen cross border collaboration, mobility and industry engagement, connecting European research, clinical, manufacturing and investment ecosystems through applied learning and capstone projects.
  • Enable participants to articulate and demonstrate projected scientific, clinical and economic value across development stages, and to align development strategies with financing, partnering and market access considerations.

Call Total Budget

€240.000

Financing percentage by EU or other bodies / Level of Subsidy or Loan

The maximum EIT Health grant that is available for development of the CIP in Biotechnology is €240.000.

The budget should be structured around two components, course development and course updates.

  • Content development and repurposing: from January 2027 to September 2027 and Budget: €200.000.
  • Content delivery, refinement, and updates: from September 2027 to March 2028 and Budget: €40.000.

The following costs will not be eligible as EIT Health assumes responsibility for such costs:

  • Learning Management System platform. This will be provided by EIT Health through the EIT Health Academy.
  • Learner recruitment and marketing related costs.

EIT Health will fund a maximum of 50% of the project’s total costs, up to the maximum EIT Health funding described above. The consortium must secure the remaining 50% co-funding from other sources (non-EIT Health)

Projects must not run longer than 15 months, with an effective start date on 01 January 2027.

After the first 9 months, the CIP pathway should be available online for registrations and programme participation.

 

Thematic Categories

  • Education and training
  • Health
  • Research, Technological Development and Innovation
  • Small-Medium Enterprises and Competitiveness

Eligibility for Participation

  • Businesses
  • Educational Institutions
  • Legal Entities
  • Other Beneficiaries
  • Researchers/Research Centers/Institutions
  • Small and Medium Enterprises (SMEs)

Eligibility For Participation Notes

In accordance with the Horizon Europe Work Programme, to be eligible for funding, the applicant must be established in one of the eligible countries, i.e.:

  • the Member States of the European Union, including their outermost regions;
  • the Overseas Countries and Territories (OCTs) linked to the Member States;
  • countries associated to Horizon Europe;  or,
  • certain low- and middle-income countries.

Legal entities, which are established in countries not listed above will be eligible for funding if their participation is considered essential for implementing the action by the EIT.

Consortium composition

  • Consortia must include at least 3 and a maximum of 5 legal entities independent from each other.
  • Consortia must include a minimum of two Higher Education Institutions (HEIs) established in two different eligible Member States, of which:
  • At least one HEI must be established in an EIT RIS region; and
  • At least one of the participating Higher Education Institutions must be authorised to award ECTS credits for the repurposed courses.
  • At least one non-academic or industry partner, expected to actively contribute to the curriculum of the repurposed courses and to the supervision of learner assessment.

Active and substantive involvement of non-academic or industry partners is essential, as a highly integrated, innovative learning by doing approach is a core principle of EIT Labelled Fellowships. Learners are expected to work both individually and in interdisciplinary teams, typically addressing authentic challenges articulated by industry and other non-academic partners.

Call Opening Date

15/07/2026

Call Closing Date

16/09/2026

EU Contact Point